AMRX Q4 2018 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q4 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$498M+69.6% YoY

Gross Profit

$193M38.9% margin

Operating Income

$23M4.7% margin

Net Income

-$9M-1.8% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+4.4%

Cash Flow

Operating Cash Flow

$260M

Free Cash Flow

$240M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$4.4B

Total Liabilities

$3.5B

Stockholders' Equity

$896M

Cash & Equivalents

$213M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$498M	$293M	+69.6%
Gross Profit	$193M	$151M	+27.7%
Operating Income	$23M	$79M	-70.5%
Net Income	-$9M	$62M	-114.2%

Revenue Segments

Rytary Family

$42M35%

Diclofenac Sodium Gel

$25M21%

Yuvafem-Estradiol

$24M20%

Epinephrine Auto-Injector Family (Generic Adrenaclick)

$18M15%

Aspirin;Dipyridamole ER Capsul

$11M9%